C-myc and cutaneous vascular neoplasms

American Journal of Dermatopathology

Volumn 35, Issue 3, 2013, Pages 364-369

  Feller, John K ^a   Mahalingam, Meera ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; c myc; Cutaneous vascular neoplasms

Indexed keywords

MYC PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANGIOSARCOMA; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; GENE EXPRESSION; HEMATOPOIESIS; HUMAN; KAPOSI SARCOMA; LYMPHEDEMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VASCULAR LESION;

BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASMS, VASCULAR TISSUE; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876718417     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31827aad83     Document Type: Article

References (46)

1. Pérez-Sayáns M, Suárez-Peñaranda JM, Pilar GD, et al. What real influence does the proto-oncogene c-myc have in OSCC behavior? Oral Oncol. 2011;47:688-692
2. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 1982;79:7824-7827
3. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79:7837-7841
4. Patel JH, Loboda AP, Showe MK, et al. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer. 2004;4:562-568
5. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004-3016
6. Gearhart J, Pashos EE, Prasad MK. Pluripotency redux - advances in stem-cell research. N Engl J Med. 2007;357:1469-1472
7. Pelengaris S, Khan M, Gerard E. c-MYC: More than just a matter of life and death. Nature. 2002;2:764-776
8. Kato GJ, Lee WM, Chen LL, et al. Max: Functional domains and interaction with c-Myc. Genes Dev. 1992;6:81-92
9. Pelengaris S, Khan M. The many faces of c-MYC. Arch Biochem Biophys. 2003;416:129-136
10. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19:1-11
11. Born TL, Frost JA, Schonthal A, et al. c-Myc cooperates with activated Ras to induce the cdc2 promoter. Mol Cell Biol. 1994;14:5710-5718
12. Mateyak MK, Obaya AJ, Adachi S, et al. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997;8:1039-1048
13. Jiun P, Hueber AO, Littlewood T, et al. c-Myc induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 1998; 13:1367-1381
14. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002;16:2530-2543
15. Pelengaris S, Littlewood T, Khan M, et al. Reversible activation of c-myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell. 1999;3:565-577
16. Knies-Bamforth UE, Fox SB, Poulsom R, et al. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res. 2004;64:6563-6570
17. Ngo CV, Gee M, Akhtar N, et al. An in vivo function for the transforming Myc protein: Elicitation of the angiogenic phenotype. Cell Growth Differ. 2000;11:201-210
18. Brandvold KA, Neiman P, Ruddell A. Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene. 2000;19:2780-2785
19. He C, Hu H, Braren R, et al. c-myc in the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo. Development. 2008; 135:2467-2477
20. Manner J, Radlwimmer B, Hohenberger P, et al. Myc high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol. 2010;176:34-39
21. Mentzel T, Schildhaus HU, Palmdedo G, et al. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: Clinicopathological; immunohistochemical and molecular analysis of 66 cases. Mod Pathol. 2012;25:75-85
22. Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcomas but not in other radiation- associated atypical vascular lesions. Genes Chromosomes Cancer. 2011;50:25-33
23. Fernandez AP, Sun Y, Tubbs RR, et al. FISH for MYC amplification and anti-MYC immunohistochemistry: Useful diagnostic tools in the assess-ment of secondary angiosarcoma and atypical vascular proliferations. J Cutan Pathol. 2012;39:234-242
24. Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol. 1994;102:757-763
25. Brenn T, Fletcher CDM. Postradiation vascular proliferations: An increasing problem. Histopathology. 2006;48:106-114
26. Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast - a clinicopathologic study of 32 cases analyzing histologic and heterogeneity and association with angiosarcoma. Am J Surg Pathol. 2008;32:943-950
27. Mandrell J, Mehta S, McClure S. Atypical vascular lesion of the breast. J Am Acad Dermatol. 2010;63:337-340
28. Gengler C, Coindre JM, Leroux A, et al. Vascular proliferations of the skin after radiation therapy for breast cancer: Clinicopathologic analysis of a series in favor of a benign process: A study from the French Sarcoma Group. Cancer. 2007;109:1584-1598
29. Di Tommaso L, Fabbri A. Cutaneous angiosarcoma arising after radiotherapy treatment of a breast carcinoma: Description of a case and review of the literature. Pathologica. 2003;95:196-202
30. Mattoch IW, Robbins JB, Kempson RL, et al. Post-radiotherapy vascular proliferations in mammary skin: A clinicopathologic study of 11 cases. J Am Acad Dermatol. 2007;57:126-133
31. Koster R, Blatt LM, Streubert M, et al. Consensus-interferon and plateletderived growth factor adversely regulate proliferation and migration of Kaposi's sarcoma cells by control of c-myc expression. Am J Pathol. 1996;149:1871-1885
32. Spandidos DA, Kaloterakis A, Yiagnisis M, et al. Ras, c-myc and c-erbB-2 oncoprotein expression in non-AIDS mediterranean Kaposi's sarcoma. Anticancer Res. 1990;10:1619-1626
33. Lubvoya B, Kellum MJ, Frisancho JA, et al. Stimulation of c-myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. J Biol Chem. 2007;282:31944-31953
34. Liu J, Martin HJ, Liao G, et al. The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-myc. J Virol. 2007;81: 10451-10459
35. Feller K, Yang S, Tung N, et al. c-myc in Kaposi's sarcoma: Analyses by fluorescent in situ hybridization and immunohistochemistry. J Eur Acad Dermatol Venereol. August 12, 2012 [Epub ahead of print].
36. Selim AGA, El-Ayat G, Naase M, et al. C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Breast. 2002;11:466-472
37. Blancato J, Singh B, Liu A, et al. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridization and immunohistochemical analyses. Br J Cancer. 2004;90:1612-1619
38. Kraehn GM, Utikal J, Udart M, et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer. 2001;84:72-79
39. Toll A, Salgado R, Yébenes G, et al. MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol. 2009;161:1112-1118
40. Christoph F, Schmidt B, Schmitz-Drager BJ, et al. Overexpression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer. 1999;84:169-173
41. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;4:820-823
42. Hopewell R, Ziff EB. The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max. Mol Cell Biol. 1995; 15:3470-3478
43. Steiger D, Furrer M, Schwinkendorf D, et al. Max-independent functions of Myc in Drosophila melanogaster. Nat Genet. 2008;40:1084-1091
44. Ponzielli R, Katz S, Barsyte-Lovejoy D, et al. Cancer therapeutics: Targeting the dark side of Myc. Eur J Cancer. 2005;41:2485-2501
45. Felsher DW, Bishop JM. Reversible tumorigenesis by myc in hematopoietic lineages. Mol Cell. 1999;4:199-207
46. Zupi G, Scarsella M, Semple SC, et al. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: Relevance of the administration sequence. Clin Cancer Res. 2005;11:1990-1998